Zobrazeno 1 - 10
of 444
pro vyhledávání: '"Paul Okunieff"'
Autor:
R. Renee Reams, Folakemi T. Odedina, John D. Carpten, Kinfe Redda, Mariana C. Stern, Janice L. Krieger, Jose Aparicio, Brooke Hensel, Nissa Askins, Andre Abreu, Angela Adams, Edward Agyare, Jamel Ali, John M. Allen, Richard Aló, Lourdes Baezconde-Garbanati, Jason Brant, Clyde P. Brown, Sarah G. Buxbaum, Pinchas Cohen, Wendy Cozen, Miriam O. Ezenwa, Sara Falzarano, Roger B. Fillingim, Hernan Flores-Rozas, Kristianna M. Fredenburg, Thomas George, Bo Han, Yong Huang, Chanita Hughes Halbert, Gebre-Egziabher Kiros, Nazarius S. Lamango, Ji-Hyun Lee, Debra E. Lyon, Duane A. Mitchell, Bereket Mochona, Jorge J. Nieva, Ite A. Offringa, Paul Okunieff, Alexander Parker, Suhn K. Rhie, Joyce M. Richey, Sherise C. Rogers, Bodour Salhia, Thomas D. Schmittgen, Richard Segal, Veronica W. Setiawan, Ukamaka Smith, Li-Ming Su, Sandra Suther, Jose Trevino, Enrique I. Velazquez-Villarreal, Fern J. Webb, Anna H. Wu, Yingwei Yao, Diana J. Wilkie
Publikováno v:
Cancer Control, Vol 30 (2023)
Introduction The Florida-California Cancer Research, Education, and Engagement (CaRE 2 ) Health Equity Center is a triad partnership committed to increasing institutional capacity for cancer disparity research, the diversity of the cancer workforce,
Externí odkaz:
https://doaj.org/article/e983d5aca8ef44e3bcc7ae504f4e6bca
Autor:
Xiaorong Zhou, Chenchen Li, Zhao Zhang, Daniel Y. Li, Jinwei Du, Ping Ding, Haiyan Meng, Hui Xu, Ronglei Li, Effie Ho, Aiguo Zhang, Paul Okunieff, Jianwei Lu, Michael Y. Sha
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Tyrosine kinase inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers including non-small-cell lung cancer (NSCLC). This study aims to evaluate
Externí odkaz:
https://doaj.org/article/b2343cf2b10446a4ab9c404bea005c66
Autor:
Natalie A. Lockney, MD, Randal Henderson, MD, Steven G. Swarts, PhD, Zhenhuan Zhang, MD, PhD, Bingrong Zhang, DVM, MD, Jennifer Li, BS, Robert A. Zlotecki, MD, PhD, Christopher G. Morris, MS, Katherine Casey-Sawicki, MA, Paul Okunieff, MD
Publikováno v:
International Journal of Particle Therapy, Vol 7, Iss 2, Pp 21-30 (2020)
Purpose: The RadTox assay measures circulating cell-free DNA released in response to radiotherapy (RT)-induced tissue damage. The primary objectives for this clinical trial were to determine whether cell-free DNA numbers measured by the RadTox assay
Externí odkaz:
https://doaj.org/article/e5d4ac6a56614569bfd5b8b8545a69f9
Autor:
I-Chia Liu, Fantine Giap, Raymond B. Mailhot-Vega, Julie A. Bradley, Nancy P. Mendenhall, Paul Okunieff, Li Lu, Michael A. Jantz, Karen Daily, Lisa Spiguel, Natalie A. Lockney
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 2, Pp 875-882 (2020)
Purpose: Radiation recall dermatitis (RRD) is a rare complication that occurs after completion of radiation therapy (RT) and initiation of a precipitating agent, most commonly chemotherapeutic medications. Various theories attempt to explain the mech
Externí odkaz:
https://doaj.org/article/c62a84f66d4c41cba092af5bed0909d2
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Abstract Multiple competing normal tissue complication probability (NTCP) models have been proposed for predicting symptomatic radiation-induced lung injury in human. In this paper we tested the efficacy of four common NTCP models applied quantitativ
Externí odkaz:
https://doaj.org/article/1426b03024384d6196d82df401bc6257
Autor:
Natalie A. Lockney, Mei Zhang, Christopher G. Morris, Romaine Charles Nichols, Paul Okunieff, Steven Swarts, Zhenhuan Zhang, Bingrong Zhang, Amy Zhang, Bradford S. Hoppe
Publikováno v:
Thoracic Cancer, Vol 10, Iss 7, Pp 1605-1611 (2019)
Background Radiation‐induced tumor immunity (RITI) influences primary tumor growth and development of metastases in preclinical cancer models with conventional radiotherapy. Antigen‐specific immune responses have also been shown for prostate canc
Externí odkaz:
https://doaj.org/article/5708af839f8a4177bc3744e1a7f862cc
Autor:
Hesham Elhalawani, Baher Elgohari, Timothy A. Lin, Abdallah S.R. Mohamed, Thomas J. Fitzgerald, Fran Laurie, Kenneth Ulin, Jayashree Kalpathy-Cramer, Thomas Guerrero, Emma B. Holliday, Gregory Russo, Abhilasha Patel, William Jones, Gary V. Walker, Musaddiq Awan, Mehee Choi, Roi Dagan, Omar Mahmoud, Anna Shapiro, Feng-Ming (Spring) Kong, Daniel Gomez, Jing Zeng, Roy Decker, Femke O.B. Spoelstra, Laurie E. Gaspar, Lisa A. Kachnic, Charles R. Thomas, Jr., Paul Okunieff, Clifton D. Fuller
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 15, Iss , Pp 83-92 (2019)
Introduction: Target delineation variability is a significant technical impediment in multi-institutional trials which employ intensity modulated radiotherapy (IMRT), as there is a real potential for clinically meaningful variances that can impact th
Externí odkaz:
https://doaj.org/article/fdbeec815fa241a584403517dfdc590d
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Purpose and Objective(s): We sought to analyze the long-term follow-up of patients treated with hypofractionated, stereotactic radiotherapy (HSRT) for oligometastases from malignancies other than breast or prostate cancer.Materials and Methods: From
Externí odkaz:
https://doaj.org/article/7a1a4bd18c0e401b88469117091833b4
Autor:
Julian C Hong, Diandra N Ayala-Peacock, Jason Lee, A William Blackstock, Paul Okunieff, Max W Sung, Ralph R Weichselbaum, Johnny Kao, James J Urbanic, Michael T Milano, Steven J Chmura, Joseph K Salama
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195149 (2018)
BackgroundRadiotherapy is increasingly used to treat oligometastatic patients. We sought to identify prognostic criteria in oligometastatic patients undergoing definitive hypofractionated image-guided radiotherapy (HIGRT).MethodsExclusively extracran
Externí odkaz:
https://doaj.org/article/c9321336f10e4946ab4f3e6ccfc7b9ac
Autor:
Ravil N. Khaybullin, Mei Zhang, Junjie Fu, Xiao Liang, Tammy Li, Alan R. Katritzky, Paul Okunieff, Xin Qi
Publikováno v:
Molecules, Vol 19, Iss 11, Pp 18676-18689 (2014)
One of the keys for successfully developing drugs against the broad spectrum of cancer cell types is structural diversity. In the current study, we focused on a family of isosteviol derivatives as potential novel antitumor agents. Isosteviol is a tet
Externí odkaz:
https://doaj.org/article/a73d4962ed7946768242e7f39ba627bf